Complete tumor resection is the most important predictor of patient survival with non-small cell lung cancer. Methods for intraoperative margin assessment after lung cancer excision are lacking. This study evaluated near-infrared (NIR) intraoperative imaging with a folate-targeted molecular contrast agent (OTL0038) for the localization of primary lung adenocarcinomas, lymph node sampling, and margin assessment. METHODS: Ten dogs with lung cancer underwent either video-assisted thoracoscopic surgery or open thoracotomy and tumor excision after an intravenous injection of OTL0038. Lungs were imaged with an NIR imaging device both in vivo and ex vivo. The wound bed was re-imaged for retained fluorescence suspicious for positive tumor margins. The tumor signal-to-background ratio (SBR) was measured in all cases. Next, 3 human patients were enrolled in a proof-of-principle study. Tumor fluorescence was measured both in situ and ex vivo. RESULTS: All canine tumors fluoresced in situ (mean Fluoptics SBR, 5.2 [range, 2.7-8.1]; mean Karl Storz SBR 1.9 [range, 1.4-2.6]). In addition, the fluorescence was consistent with tumor margins on pathology. Three positive lymph nodes were discovered with NIR imaging. Also, a positive retained tumor margin was discovered upon NIR imaging of the wound bed. Human pulmonary adenocarcinomas were also fluorescent both in situ and ex vivo (mean SBR, > 2.0). CONCLU-SIONS: NIR imaging can identify lung cancer in a large-animal model. In addition, NIR imaging can discriminate lymph nodes harboring cancer cells and also bring attention to a positive tumor margin. In humans, pulmonary adenocarcinomas fluoresce after the injection of the targeted contrast agent.
INTRODUCTION
Lung cancer is the leading cause of cancer-related death in the United States with an estimated mortality of 164,000 patients in 2014. 1 Surgical resection is the mainstay of treatment for patients with stage I and II non-small cell lung cancer and for a subset of patients with stage IIIA non-small cell lung cancer. 2, 3 The most important predictors of patient survival are accurate staging and complete surgical resection. Specifically, patients with complete surgical resection have significantly better survival than those with partial or incomplete resection. [4] [5] [6] [7] [8] Surgical precision depends on complete tumor removal with disease-free margins and identification of regional metastatic disease. The visual information, tactile cues, and experience used by surgeons to identify a tumor and surgical margins are subjective and may lead to erroneous decisions. Currently, there are minimal intraoperative techniques for margin detection for lung cancer. One technique, frozen section, is costly and time-consuming and requires a specialized pathologist. 9 Therefore, there is a need for reliable, objective, real-time imaging during surgery to delineate a tumor from normal tissue and evaluate regional lymph nodes and local structures for metastatic disease.
Intraoperative molecular imaging provides objective, real-time visualization of tumors during surgery and allows the accurate resection of tumors and adequate margins of normal tissue. Different approaches to fluorescence imaging, including various optical contrast agents, antibody conjugates, peptide conjugates, and tumor-activated probes, have been investigated. The potential utility of intraoperative fluorescence-guided tumor resection has been evaluated in preclinical studies and in a limited number of patients with breast, ovarian, pancreatic, and hepatic cancers, gliomas, and non-small cell lung cancers. [10] [11] [12] [13] [14] [15] [16] [17] [18] We have shown that near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) can identify lung tumors and other solid tumors, including breast cancer and thymomas, in canine and human patients. 12, 14, 15, 19, 20 ICG is thought to accumulate in tumors through leaky tumor vasculature and decreased lymphatic drainage (the enhanced permeability and retention effect); it is effective but nonspecific. [21] [22] [23] Our group has had success with using a folatetargeted visible-spectrum optical contrast agent, folatefluorescein isothiocyanate (FITC), for the localization and margin assessment of pulmonary adenocarcinomas and ovarian cancers and metastases. [24] [25] [26] Folate receptor a is highly expressed in several cancer types, including ovarian cancer, colorectal cancer, and >80% of pulmonary adenocarcinomas. It, therefore, provides a reliable target for optical contrast agents. Folate-FITC has an excitation wavelength of 495 nm and emits at 520 nm. Although successful, our studies using folate-FITC were limited by autofluorescence from surrounding normal tissue and a lack of depth of penetration into the lung. In contrast to visible-spectrum agents, molecularly targeted dyes, fluorescing in the NIR spectrum, have the potential to overcome these challenges.
We hypothesized that a novel folate receptor-targeted NIR dye would identify lung tumors during surgery in a pilot study using spontaneously occurring canine primary lung tumors, which provide an excellent largeanimal model of non-small cell lung cancer in humans. First, we showed that the NIR folate receptor-targeted dye could localize in lung tumors and lymph nodes, and then we demonstrated that the retained fluorescence provided information regarding tumor margins. Lastly, we performed a proof-of-principle study of NIR intraoperative molecular imaging in 3 human patients with preoperatively diagnosed pulmonary adenocarcinoma.
MATERIALS AND METHODS

Folate Receptor-Targeted Contrast Agent
An NIR folate receptor-targeted contrast agent was produced at clinical grade according to good manufacturing practice (GMP) conditions by On Target Laboratories, LLC, and was then supplied on a non-GMP basis to the University of Pennsylvania School of Veterinary Medicine. The contrast agent, known as OTL0038, is a folate analogue ligand conjugated with an indole cyanine-like green dye. OTL0038 excites at 774 to 775 nm and emits at 794 to 796 nm. The agent targets the folate receptor and is internalized into the cytoplasm. All vials of OTL0038 were supplied after the approval of the investigational medicinal product dossier documentation according to the US Food and Drug Administration. The imaging agent was stored, recorded, and monitored before its release by the hospital pharmacy according to the US Food and Drug Administration and Good Clinical Practice guidelines. OTL0038 was dissolved in phosphate-buffered saline (PBS) and injected intravenously at a dose of 0.185 mg/kg over a period of 5 minutes 2 to 3 hours before surgery.
Our dose of 0.185 mg/kg for intravenous OTL0038 was based on preclinical small-animal studies performed in our laboratory. In these studies, which have not yet been published, we found that optimal tumor imaging occurred with intravenous injection and imaging performed 2 to 3 hours after infusion. This was the lowest dose as well as the optimal timing at which tumor fluorescence was brightest in comparison with background fluorescence. In addition, we found no evidence of animal toxicity from OTL0038 infusion or imaging. In a separate and currently ongoing phase 1 clinical trial, our preliminary data show no toxicity in patients except for 1 instance of a grade 1 hypersensitivity reaction consisting of a minor rash, which was resolved with an antihistamine and discontinuation of the drug infusion. Likewise, the structure of OTL0038 is similar to the structure of ICG. ICG has been well tolerated for decades with a favorable safety profile and is primarily used for perfusion imaging.
Imaging Systems
Fluorescence imaging was performed in 4 cases with a commercial NIR imaging system (Fluobeam; Fluoptics, Grenoble, France). NIR excitation light was generated by a laser emitting at 785 nm. The laser illuminated a 6-cm diameter area at a 17-cm working distance. The optical head contained a sensitive charged-coupled device camera allowing visualization of NIR fluorescence in the surgical field.
An NIR-optimized thoracoscopic system was used in 6 cases (Karl Storz GmbH & Co. KG, Tuttlingen, Germany). Light was generated by a xenon light source (20133701-1 D-light P; Karl Storz) that included an integrated filter turret, which permitted the user to switch appropriate filters into the light-transmission pathway. The specifically designed dichroic filter set enabled the excitation of OTL0038 fluorescence at the wavelength of maximum absorption in parallel with background illumination of the surgical field. Switching the filter out of the pathway permitted standard white-light observation. OTL0038 fluorescence was visualized with a high-definition, NIR-imaging, 3-chip charge-coupled device camera (22220085-3 H3-Z FI camera head and 22201011-112 Image 1 HUB camera control unit; Karl Storz) coupled to a 308, 10-mm Hopkins forward-oblique telescope (26003 BGA; Karl Storz). The telescope transmits light in the OTL0038 emission-wavelength maximum range.
Canine Subjects
Between April and November 2014, 10 dogs with primary lung tumors that were deemed surgical candidates were recruited from the University of Pennsylvania School of Veterinary Medicine. The canine study was approved by the university's institutional animal care and use committee. The consent document was approved by the veterinary school's privately owned animal protocol committee, and written informed consent was obtained from all owners.
The imaging systems were used to inspect the surgical field before and after the pulmonary resection. Fluorescence readings were taken from the tumor and grossly normal lung in the affected lobe. The tumor periphery was imaged in 4 radial directions (12, 3, 6 , and 9 o'clock positions). Grossly normal lung tissue extending 5 and 10 mm away from the tumor periphery was then imaged where possible, and the data were used as background readings. After lobectomy, the hilus of the lobe and any visible bronchial lymph nodes were imaged in NIR, and excised specimens were imaged ex vivo before their submission for histopathological evaluation. The tumor margins were determined by fluorescence, marked with sutures, and subsequently compared with histopathological margins.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were washed in xylene (2 3 7 0 ), which was followed by ethanol (100% 2 3 4 0 , 95% 2 3 1 0 , and 70% 1 3 1 0 ) before antigen retrieval with a Citra solution (HK086-9K; Biogenex, Freemont, Calif). The sections were boiled and then left for 25 minutes in the hot buffer. Endogenous peroxidases were quenched with 3% hydrogen peroxide for 15 minutes and washed. Biotin was blocked with an avidinbiotin blocking kit according to the manufacturer's instructions (SP-2001; Vector Labs, Burlingame, Calif). Protein blocking was performed at room temperature for 15 minutes (StartingBlock T20 37539; Thermo Scientific, Rockford, Ill).
The primary antibody, rabbit anti-FOLR1/folate receptor a (LS-B572; LSBio), was diluted 1:750 in an antibody diluent (003118; Life Technologies, Fredrick, Md) and applied to the sections for 60 minutes at 378C. The slides were then washed in PBS for 5 minutes 2 consecutive times (2 3 5 0 ), and a biotinylated anti-rabbit secondary (BA-1000; Vector Labs) was applied for 30 minutes at 378C. After PBS washes (2 3 5 0 ), an avidinbiotin complex reagent (Vectastain Elite PK-6100; Vector Labs) was applied for 30 minutes at 378C. Slides were washed in PBS (2 3 5 0 ), and the signal was developed with a 3,3 0 -diaminobenzidine reagent kit (SK-4100; Vector Labs). Slides were counterstained with hematoxylin, dehydrated through ethanols, cleared in xylene, and mounted with CytoSeal XYL (8312-4; Thermo Scientific). 
Human Trial
Between March and June 2015, 3 patients diagnosed with pulmonary adenocarcinoma were enrolled in a proof-of-principle study. The study was approved by the institutional review board of the University of Pennsylvania, and all patients gave informed consent. Patients underwent computed tomography scanning with a 1-mm slice thickness; this was reviewed by a radiologist to confirm the presence of a pulmonary nodule. Subsequently, each patient underwent transthoracic or transbronchial biopsy demonstrating cancer cells before enrollment.
Surgeons performed typical video-assisted thoracoscopic surgery (VATS) and located the lung nodule with thoracoscopy, finger palpation, and NIR fluorescence. All NIR imaging was performed with the Karl Storz thoracoscopic system.
After NIR imaging, the specimen was re-imaged on the back-table before its submission to pathology.
RESULTS
NIR Intraoperative Fluorescence Imaging Identifies Pulmonary Adenocarcinoma In Situ
Ten dogs were enrolled in the study. Their ages ranged from 7 to 13 years (median, 11 years), and their weights ranged from 3.8 to 37.0 kg (median, 13.0 kg). The OTL0038 infusions were well tolerated, and no adverse reactions were observed. Six dogs had pulmonary carcinomas, and 4 had adenocarcinomas, which were confirmed with preoperative biopsy. The mean tumor size was 6.1 cm (range, 3.0-10.0 cm). The canine characteristics are summarized in Table 1 .
Four dogs underwent open thoracotomy and were imaged with the Fluoptics system, and 6 underwent VATS excision and were imaged with the Karl Storz NIR endoscopic system. NIR fluorescence imaging clearly identified the tumor in all cases. The mean tumor fluorescence averaged from all 4 quadrants of the tumor was 33,390 AU (range, 9524-52,415 AU) with the Fluoptics system and (Fig. 2) .
A stitch was placed with fluorescence guidance at the macroscopic tumor border and in the normal lung in all radial directions before submission to pathology. Pathology confirmed the presence of tumor at the areas of fluorescence and the presence of normal lung tissue at the location of background fluorescence. In addition, immunohistochemistry confirmed 2 1 or 3 1 folate receptor staining in all tumor specimens.
NIR Fluorescence Imaging Identifies Positive Lymph Nodes
After tumor excision, the specimen was re-imaged for evidence of lymph nodes with both traditional white light and the NIR imaging device. In accordance with the standard of care for canine subjects, no significant dissection was performed to search for lymph nodes. However, in 3 cases, NIR imaging with the Fluoptics imaging device identified markedly fluorescent regional bronchial lymph nodes with SBRs of 2, 4.3, and 5, respectively (P < .001 in all cases), and they were sent for pathological correlation (Fig. 3) . All 3 fluorescent lymph nodes were found to be metastatic for tumor cells by a board-certified veterinarian pathologist. Likewise, 1 additional lymph node was found with traditional white-light imaging. In this case, the lymph node was also imaged with the NIR imaging device. However, unlike the previously described 3 nodes, this bronchial lymph node did not fluoresce either in comparison with normal tissue. After excision and biopsy, this lymph node was tumor-negative according to hematoxylin-eosin staining.
The fluorescent lymph nodes were stained with immunohistochemistry and were found to be 3 1 folate receptor-positive in all cases. In the case of the nonfluorescent lymph node, which was found to be negative for tumor metastasis, immunohistochemistry found weakly positive (11) staining.
NIR Fluorescence Imaging Identifies a Positive Tumor Margin
After tumor resection, NIR imaging was used to re-image the wound bed to look for residual fluorescence concerning for retained tumor. In 9 of 10 cases, no fluorescence was noted in the wound bed (mean SBR, < 1.2). In all 9 instances, the resected specimen was noted to have widely negative margins (tumor located > 1 cm from the margin).
However, in 1 case, fluorescence was noted on the hilum during both ex vivo and wound-bed imaging. This case is detailed here: Buckwheat was an 11-year-old Labrador retriever. He presented for coughing to the surgeon (D.H.). He was found to have a 5-cm biopsy-proven pulmonary adenocarcinoma in his right caudal lobe. Consent was given for surgery, and he tolerated an OTL0038 infusion 2.5 hours before surgery. He underwent imaging with the Karl Storz thoracoscopic imaging system. His tumor was fluorescent with an in vivo SBR of 1.4. After specimen excision and imaging, the wound bed was reimaged, and this demonstrated an area of retained fluorescence in the bronchus (SBR vs adjacent normal bronchus, 1.8; P < .001; Fig. 4 ). This additional fluorescent bronchial tissue was removed. Biopsy and hematoxylin-eosin staining of this tissue confirmed foci of carcinoma at the resected bronchial margin.
Canine Outcomes
All dogs survived the perioperative period and were discharged from the hospital. The 3 dogs with tumorpositive lymph nodes survived less than 4 months (range, 1-3 months). The dog with the fluorescent wound bed and corresponding tumor-positive margin was alive 9 months after surgery but had evidence of tumor recurrence on follow-up thoracic radiographs obtained with his local veterinarian. All remaining dogs were alive more than 12 months after surgery and showed no clinical evidence of cancer recurrence.
OTL0038 Localizes to Pulmonary Adenocarcinoma in Humans
After the success of our animal study, we enrolled 3 human patients with preoperatively diagnosed pulmonary adenocarcinoma in a proof-of-principle clinical trial. All patients underwent NIR imaging with the Karl Storz thoracoscope. All tumors were found to be fluorescent in vivo (mean SBR, 2.8; range, 2.2-3.4) and ex vivo (mean SBR, 3.3; range, 2.8-3.7). One patient is discussed here: Patient 1 was a 55-year-old female with a 45-pack-year smoking history. She presented to her primary care physician with an incidental pulmonary nodule located in the left lower lobe and noted on a computed tomography scan. She underwent transthoracic needle biopsy and was diagnosed with pulmonary adenocarcinoma. She underwent an OTL0038 injection of 0.025 mg/kg via the antecubital vein 3 hours before imaging with no adverse events. After traditional localization, the Karl Storz NIR thoracoscope was turned on. The pulmonary nodule was noted to be fluorescent with an in situ SBR of 3.4 (Fig. 5) . The nodule was excised via wedge resection and was fluorescent on the back-table, and there was no fluorescence noted at the staple line. Upon re-imaging of the wound bed, no additional fluorescence, which would have indicated disease left behind, was seen. Final pathology confirmed a 3.5-cm pulmonary adenocarcinoma with negative margins. All patient demographics and tumor 
DISCUSSION
Intraoperative margin assessment of solid tumors is important for complete resection, clinical staging, and postoperative planning. Different approaches to improving intraoperative lung tumor margin assessment have been used with varying success. For example, frozen sections of representative tumor margins can be evaluated by pathologists during surgery. However, the evaluation of an entire margin would require thousands of sections, which would be impractical. 27 Other methods of tumor detection include ultrasound, which is unlikely to identify small residual tumor foci, and radiofrequency spectroscopy, which is not easily adaptable to the clinical surgery setting. 28, 29 The limitations of margin-assessment modalities have led our group to investigate real-time tumor imaging with a variety of fluorescent probes and imaging systems. Spontaneous canine lung cancer occurs in animals with owners who smoke tobacco and is most often adenocarcinoma. In this study, intraoperative molecular imaging with an NIR folate-targeted fluorescent agent and 2 NIR imaging devices identified canine lung tumors and their margins in all canine and human cases. In addition, OTL0038 also identified 3 tumor-positive regional lymph nodes and 1 tumor-positive surgical margin. These results illustrate the potential for NIR fluorescent imaging to accurately detect primary and regional pulmonary metastatic disease, and this may allow more complete resections.
As an NIR agent, OTL0038 fluorescent light has the added benefit of improved depth of penetration for imaging tumors deeper within the lung tissue in comparison with visible-spectrum agents such as the previously described folate-FITC. 30 OTL0038 is also a targeted agent, and this should allow improved depth of penetration, decreased local tissue autofluorescence, and adenocarcinoma-specific binding. In addition, NIR imaging delivers 10 5 less energy than a chest radiograph, and this makes it safe for patients. 31 We acknowledge several limitations of this study. First, because of our relatively small sample size, we had 1 positive margin correlating with retained tumor-bed fluorescence. In addition, veterinary surgeons do not routinely visualize and remove all lymph nodes in surgery for canine lung cancer, so we were able to sample only nodes that were obvious and easy to dissect. As such, we will rely on our human trial to investigate the implications of lymph node fluorescence.
Second, there is a need for the development of intraoperative fluorescence quantification. In this study, we used postoperative fluorescence calculations for the measurement of the SBR. Although this provides an accurate assessment of fluorescence, it does not provide quantitative data to the surgeon in real time.
Intraoperative molecular imaging would be valuable to thoracic surgeons for the localization of small pulmonary tumors, which are difficult to feel and see with traditional VATS. A fluorescent tumor would be easier to localize, and this might reduce both the need for conversion to open thoracotomy and the operative time. In addition, minimally invasive thorascopic techniques have become standard treatment for early-stage non-small cell lung cancer in humans. [32] [33] [34] [35] [36] Importantly, the Karl Storz imaging device incorporates NIR imaging technology into a 308 10-mm telescope. Likewise, although not used in this large-animal study, robotic surgery may be performed with the da Vinci Si surgical system equipped with Firefly technology, which allows NIR imaging. This will be pertinent to research of this type in an upcoming human trial as robotic surgery increases in popularity. [37] [38] [39] The results of this study support the use of NIR thorascopic surgery with an appropriately targeted NIR contrast agent for the investigation of early-stage nonsmall cell lung cancer to delineate tumor margins and identify metastatic lymph nodes. A clinical trial to validate these preliminary results is now underway
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